+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Protein Kinase Inhibitors. From Discovery to Therapeutics

  • Book

  • May 2022
  • Elsevier Science and Technology
  • ID: 5483908

Protein Kinase Inhibitors: From Discovery to Therapeutics offers a foundational, pragmatic overview of protein kinases inhibitors and their potential role in disease modulation and treatment. Here, international experts in the field offer an integrated discussion of kinase inhibitor biology, biomarker discovery, and methods for drug design and development. After a brief overview of kinases and kinase inhibitors, subsequent chapters discuss individual kinases that are representative of the wider kinases and kinase families, including their roles in disease pathogenesis, underlying mechanisms, potential inhibitors and their modes of action for therapeutic modulation.

Several potential drugs under different stages of clinical trials are discussed, including their relevance to cancer, diabetes, obesity, cardiovascular, neurological, and auto-immune and inflammatory disease, among other disorders. The book also addresses the challenges and opportunities for future kinase inhibitor development.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

1. Kinase Inhibitors: An Overview 2. Protein Kinase Inhibitors and cancer targeted therapy 3. Drug discovery for cancer therapy with special reference to inhibitors of protein kinase pathway 4. An insight on PI3K/Akt/mTOR inhibitors in cancer: opportunity and translational perspectives 5. Recent advances in the therapeutic development of ERK inhibitors 6. Emerging small-molecule inhibitors of ATM kinase targeting cancer therapy 7. Targeting Pyruvate Kinase M2 Signaling for Development of Effective Cancer Therapy 8. Serum and glucocorticoid-regulated kinase 1: A potential target for anticancer therapy 9. AKT inhibitors in cancer therapy 10. Aurora kinase: An emerging potential target in therapeutics 11. The Retroactive and Future Potentials of Aurora Kinases in the Treatment of Cancer 12. Targeting the altered tyrosine kinases in colorectal cancer: from inhibitors to drugs 13. PTEN-induced kinase1 (PINK1): Structure, Functions and Role in Human Disease 14. Rho associated protein kinase 1 and 2 (ROCK1&ROCK2) as a potential emerging therapeutic drug target in Alzheimer's disease 15. PDK inhibitors as therapeutic agents: An Overview 16. Polo-like kinases (PLKs): an antimitotic target 17. Src Kinase: An Attractive Therapeutic Target for Prostate Cancer 18. Kinase inhibition in Alzheimer's disease 19. Therapeutic Targeting of Glycogen Synthase Kinase-3: Strategy to address neurodegenerative diseases 20. Microtubule Affinity Regulating Kinase 4: a potential drug target from cancers to neurodegenerative diseases 21. Receptor tyrosine kinase-like orphan receptors ROR1/2: Insights into the mechanism of action, inhibition, and therapeutic potentialIndrakant 22. Therapeutic Potential of Leucine Rich Repeat Kinase 2 (LRRK2) Inhibitors for Parkinson's Disease Treatment 23. Calcium calmodulin dependent protein kinase as potential drug target 24. Therapeutics of Platelet derived growth factor (PDGF) and signaling in different organs 25. EGFRC797S mutation and fourth generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) 26. Bacterial Histidine Kinases as potential Antibacterial Drug Targets 27. Bacterial Protein Kinases: a target to inhibit the bacterial infections 28. Nanotechnology-based targeted delivery systems for Protein Kinase inhibitors in Cancer therapy

Authors

Md. Imtaiyaz Hassan Assistant Professor, Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India. Dr. Md. Imtaiyaz Hassan, Ph.D., FRSB., FRSC., is Assistant Professor at the Centre for Interdisciplinary Research in Basic Sciences, in Jamia Millia Islamia, New Delhi, India. His research focuses on and design and development of potent and selective kinase inhibitors, as well as understanding the mechanism of folding and dynamic behavior of potential drug targets. Dr. Hassan has published widely in such peer reviewed journals as the International Journal of Biological Macromolecules, Spectrochimica Acta, Scientific Reports, and the OMICS A Journal of Integrative Biology. Saba Noor Research Associate, Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India. Dr. Saba Noor is a Research Associate at the Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India. Dr. Noor has expertise in molecular oncology, and her current research interests lie in development of kinase inhibitors for use in cancer therapeutics. She has published in such peer reviewed journals as Frontiers in Microbiology and International Journal of Biological Macromolecules, among other journals.